Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Marqibo in Metastatic Uveal Melanoma
NCT00506142Phase 2Completed
- Sponsor
- Spectrum Pharmaceuticals, Inc.
- Start
- Nov 2007
- Primary completion
- Dec 2014
- Modality
- Covalent Small Molecules, Classical Binding Small Molecules, Nucleic Acid-Directed Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of vincristine sulfate liposome injection in Uveal melanoma (UM) (2 cohorts), sponsored by Spectrum Pharmaceuticals, Inc. Primary endpoint: Disease Control Rate at 1 year. Started Nov 2007; status: completed.
02
Drugs
vincristine sulfate liposome injection
03
Conditions
Uveal melanoma (UM)
Beyond the preview
Go deeper on NCT00506142.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00506142.